Welcome to the Instem Investor Centre


Instem (AIM:INS.L) is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation and regulatory submission management stages.

Instem’s Early Development Applications (EDAs) are used to:

  • collect, analyse and report complex scientific data;
  • comply with regulatory reporting requirements;
  • improve quality, consistency and efficiency of information reporting; and
  • reduce the time of critical path R&D activities.

Instem’s solutions are supplied to an international blue chip customer base including organizations such as AstraZeneca, GlaxoSmithKline,Charles River Laboratories and the National Institutes of Health.

Share price

Instem Plc 'very positive about 2017 clinical opportunites'

Instem Plc ( LON:INS ) said the performance of its clinical arm had further deteriorated since...

Instem clinical business still struggling, upbeat on next year

There are a “range of possible outcomes” for the year, Instem said. The outlook for 2017 remains “en...

Instem says R&D productivity at "all-time high"

Instem currently has more than 500 clients across the globe. It reports a 98% client retention rate,...

Instem boss Phil Reason hails super first half and talks new business and growth

Instem Plc had a “super” first half, according to chief executive Phil Reason who joined Proact...

New Research Note 'A Day to Remember' - Instem Analyst & Investor Day

Featured Video

CEO hails super first half and talks new business and growth

Instem is a robust business, with net cash and a valuable customer base delivering high levels of recurring revenue. The business continues to increase its strong global market share and is well positioned to take advantage of the structural changes in the drug development industry. Both the regulatory and fiscal environments continue to be favourable to Instem, driving demand for all areas of our product and services suite.
Our acquisitions of Logos Technologies, Perceptive Instruments, Samarind Ltd and NOTOCORD mark important strategic moves into the early phase clinical, in vitro and Regulatory Information Management marketplaces whilst providing additional cross-selling opportunities. Our clients now have the ability to turn to Instem as a global supplier for their data management needs across broader segments. We will continue to expand the Group's reach into complementary scientific domains as part of our growth strategy.

Phil Reason,
Chief Executive